Repository logo
 

Long-Term Safety, Immunologic Response, and Imaging Outcomes following Neural Stem Cell Transplantation for Pelizaeus-Merzbacher Disease.

Accepted version
Peer-reviewed

Type

Article

Change log

Authors

Gupta, Nalin 
Henry, Roland G 
Kang, Sang-Mo 
Strober, Jonathan 
Lim, Daniel A 

Abstract

Four boys with Pelizaeus-Merzbacher disease, an X-linked leukodystrophy, underwent transplantation with human allogeneic central nervous system stem cells (HuCNS-SC). Subsequently, all subjects were followed for an additional 4 years in this separate follow-up study to evaluate safety, neurologic function, magnetic resonance imaging (MRI) data, and immunologic response. The neurosurgical procedure, immunosuppression, and HuCNS-SC transplantation were well tolerated and all four subjects were alive at the conclusion of the study period. At year 2, all subjects exhibited diffusion MRI changes at the implantation sites as well as in more distant brain regions. There were persistent, increased signal changes in the three patients who were studied up to year 5. Two of four subjects developed donor-specific HLA alloantibodies, demonstrating that neural stem cells can elicit an immune response when injected into the CNS, and suggesting the importance of monitoring immunologic parameters and identifying markers of engraftment in future studies.

Description

Keywords

Pelizaeus-Merzbacher disease, leukodystrophy, myelin, neural stem cells, neurodegenerative disease, oligodendrocyte, pediatric, transplantation, Brain, Child, Preschool, Follow-Up Studies, HLA Antigens, Humans, Infant, Isoantibodies, Magnetic Resonance Imaging, Male, Neural Stem Cells, Pelizaeus-Merzbacher Disease, Severity of Illness Index, Stem Cell Transplantation, Transplantation, Homologous, Treatment Outcome

Journal Title

Stem Cell Reports

Conference Name

Journal ISSN

2213-6711
2213-6711

Volume Title

13

Publisher

Elsevier BV

Rights

All rights reserved
Sponsorship
Medical Research Council (MC_PC_12009)
RGH receives research funding from Sanofi-Genzyme, Roche/Genentech, Medday. Consultancy from Novartis, Medday, Roche, Sanofi-Genzyme, Abbvie. Educational programs from Sanofi-Genzyme, TEVA. This clinical study was supported by StemCells Inc.